Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients

Judith E. Raber-Durlacher, Inger Von Bültzingslöwen, Richard M. Logan, Joanne Bowen, Abdul Rahman Al-Azri, Hele Everaus, Erich Gerber, Jesùs Garcia Gomez, Bo G. Pettersson, Yoshihiko Soga, Fred K L Spijkervet, Wim J E Tissing, Joel B. Epstein, Sharon Elad, Rajesh V. Lalla

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Purpose: The aim of this project was to review the literature and define clinical practice guidelines for the use of cytokines and growth factor agents for the prevention or treatment of oral mucositis induced by cancer chemotherapy or radiotherapy. Methods: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: Recommendation, Suggestion, No guideline possible. Results: Sixty-four clinical studies across 11 interventions were evaluated. A recommendation was made for the use of recombinant human KGF-1 (palifermin) at a dose of 60 μg/kg per day for 3 days prior to conditioning treatment and for 3 days post-transplant for prevention of oral mucositis in patients receiving high-dose chemotherapy and total body irradiation followed by autologous stem cell transplantation for hematological malignancies. A suggestion was made against using granulocyte macrophage colony-stimulating factor mouthwash for the prevention of oral mucositis in the setting of high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation. No guideline was possible for any other cytokine or growth factor agents due to inconclusive evidence. Conclusions: Of the cytokine and growth factor agents studied for oral mucositis, the evidence only supports use of palifermin in the specific population listed above. Additional well-designed research is needed on other cytokine and growth factor interventions and in other cancer treatment settings.

Original languageEnglish
Pages (from-to)343-355
Number of pages13
JournalSupportive Care in Cancer
Volume21
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Stomatitis
Intercellular Signaling Peptides and Proteins
Fibroblast Growth Factor 7
Cytokines
Stem Cell Transplantation
Guidelines
Drug Therapy
Neoplasms
Mouthwashes
Mucositis
Whole-Body Irradiation
Hematologic Neoplasms
Therapeutics
Granulocyte-Macrophage Colony-Stimulating Factor
Practice Guidelines
Radiotherapy
Transplants
Research
Population

Keywords

  • Cytokines
  • Growth factors
  • Guidelines
  • Mucositis
  • Systematic review

ASJC Scopus subject areas

  • Oncology

Cite this

Raber-Durlacher, J. E., Von Bültzingslöwen, I., Logan, R. M., Bowen, J., Al-Azri, A. R., Everaus, H., ... Lalla, R. V. (2013). Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 21(1), 343-355. https://doi.org/10.1007/s00520-012-1594-5

Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. / Raber-Durlacher, Judith E.; Von Bültzingslöwen, Inger; Logan, Richard M.; Bowen, Joanne; Al-Azri, Abdul Rahman; Everaus, Hele; Gerber, Erich; Gomez, Jesùs Garcia; Pettersson, Bo G.; Soga, Yoshihiko; Spijkervet, Fred K L; Tissing, Wim J E; Epstein, Joel B.; Elad, Sharon; Lalla, Rajesh V.

In: Supportive Care in Cancer, Vol. 21, No. 1, 01.2013, p. 343-355.

Research output: Contribution to journalArticle

Raber-Durlacher, JE, Von Bültzingslöwen, I, Logan, RM, Bowen, J, Al-Azri, AR, Everaus, H, Gerber, E, Gomez, JG, Pettersson, BG, Soga, Y, Spijkervet, FKL, Tissing, WJE, Epstein, JB, Elad, S & Lalla, RV 2013, 'Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients', Supportive Care in Cancer, vol. 21, no. 1, pp. 343-355. https://doi.org/10.1007/s00520-012-1594-5
Raber-Durlacher JE, Von Bültzingslöwen I, Logan RM, Bowen J, Al-Azri AR, Everaus H et al. Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Supportive Care in Cancer. 2013 Jan;21(1):343-355. https://doi.org/10.1007/s00520-012-1594-5
Raber-Durlacher, Judith E. ; Von Bültzingslöwen, Inger ; Logan, Richard M. ; Bowen, Joanne ; Al-Azri, Abdul Rahman ; Everaus, Hele ; Gerber, Erich ; Gomez, Jesùs Garcia ; Pettersson, Bo G. ; Soga, Yoshihiko ; Spijkervet, Fred K L ; Tissing, Wim J E ; Epstein, Joel B. ; Elad, Sharon ; Lalla, Rajesh V. / Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. In: Supportive Care in Cancer. 2013 ; Vol. 21, No. 1. pp. 343-355.
@article{961274ffcb4c4a88807654d2953bc2e5,
title = "Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients",
abstract = "Purpose: The aim of this project was to review the literature and define clinical practice guidelines for the use of cytokines and growth factor agents for the prevention or treatment of oral mucositis induced by cancer chemotherapy or radiotherapy. Methods: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: Recommendation, Suggestion, No guideline possible. Results: Sixty-four clinical studies across 11 interventions were evaluated. A recommendation was made for the use of recombinant human KGF-1 (palifermin) at a dose of 60 μg/kg per day for 3 days prior to conditioning treatment and for 3 days post-transplant for prevention of oral mucositis in patients receiving high-dose chemotherapy and total body irradiation followed by autologous stem cell transplantation for hematological malignancies. A suggestion was made against using granulocyte macrophage colony-stimulating factor mouthwash for the prevention of oral mucositis in the setting of high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation. No guideline was possible for any other cytokine or growth factor agents due to inconclusive evidence. Conclusions: Of the cytokine and growth factor agents studied for oral mucositis, the evidence only supports use of palifermin in the specific population listed above. Additional well-designed research is needed on other cytokine and growth factor interventions and in other cancer treatment settings.",
keywords = "Cytokines, Growth factors, Guidelines, Mucositis, Systematic review",
author = "Raber-Durlacher, {Judith E.} and {Von B{\"u}ltzingsl{\"o}wen}, Inger and Logan, {Richard M.} and Joanne Bowen and Al-Azri, {Abdul Rahman} and Hele Everaus and Erich Gerber and Gomez, {Jes{\`u}s Garcia} and Pettersson, {Bo G.} and Yoshihiko Soga and Spijkervet, {Fred K L} and Tissing, {Wim J E} and Epstein, {Joel B.} and Sharon Elad and Lalla, {Rajesh V.}",
year = "2013",
month = "1",
doi = "10.1007/s00520-012-1594-5",
language = "English",
volume = "21",
pages = "343--355",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients

AU - Raber-Durlacher, Judith E.

AU - Von Bültzingslöwen, Inger

AU - Logan, Richard M.

AU - Bowen, Joanne

AU - Al-Azri, Abdul Rahman

AU - Everaus, Hele

AU - Gerber, Erich

AU - Gomez, Jesùs Garcia

AU - Pettersson, Bo G.

AU - Soga, Yoshihiko

AU - Spijkervet, Fred K L

AU - Tissing, Wim J E

AU - Epstein, Joel B.

AU - Elad, Sharon

AU - Lalla, Rajesh V.

PY - 2013/1

Y1 - 2013/1

N2 - Purpose: The aim of this project was to review the literature and define clinical practice guidelines for the use of cytokines and growth factor agents for the prevention or treatment of oral mucositis induced by cancer chemotherapy or radiotherapy. Methods: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: Recommendation, Suggestion, No guideline possible. Results: Sixty-four clinical studies across 11 interventions were evaluated. A recommendation was made for the use of recombinant human KGF-1 (palifermin) at a dose of 60 μg/kg per day for 3 days prior to conditioning treatment and for 3 days post-transplant for prevention of oral mucositis in patients receiving high-dose chemotherapy and total body irradiation followed by autologous stem cell transplantation for hematological malignancies. A suggestion was made against using granulocyte macrophage colony-stimulating factor mouthwash for the prevention of oral mucositis in the setting of high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation. No guideline was possible for any other cytokine or growth factor agents due to inconclusive evidence. Conclusions: Of the cytokine and growth factor agents studied for oral mucositis, the evidence only supports use of palifermin in the specific population listed above. Additional well-designed research is needed on other cytokine and growth factor interventions and in other cancer treatment settings.

AB - Purpose: The aim of this project was to review the literature and define clinical practice guidelines for the use of cytokines and growth factor agents for the prevention or treatment of oral mucositis induced by cancer chemotherapy or radiotherapy. Methods: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: Recommendation, Suggestion, No guideline possible. Results: Sixty-four clinical studies across 11 interventions were evaluated. A recommendation was made for the use of recombinant human KGF-1 (palifermin) at a dose of 60 μg/kg per day for 3 days prior to conditioning treatment and for 3 days post-transplant for prevention of oral mucositis in patients receiving high-dose chemotherapy and total body irradiation followed by autologous stem cell transplantation for hematological malignancies. A suggestion was made against using granulocyte macrophage colony-stimulating factor mouthwash for the prevention of oral mucositis in the setting of high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation. No guideline was possible for any other cytokine or growth factor agents due to inconclusive evidence. Conclusions: Of the cytokine and growth factor agents studied for oral mucositis, the evidence only supports use of palifermin in the specific population listed above. Additional well-designed research is needed on other cytokine and growth factor interventions and in other cancer treatment settings.

KW - Cytokines

KW - Growth factors

KW - Guidelines

KW - Mucositis

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=84874115252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874115252&partnerID=8YFLogxK

U2 - 10.1007/s00520-012-1594-5

DO - 10.1007/s00520-012-1594-5

M3 - Article

C2 - 22987094

AN - SCOPUS:84874115252

VL - 21

SP - 343

EP - 355

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 1

ER -